Oxford Biomedica PLC Director Dealings (3525I)

TIDMOXB

RNS Number : 3525I

Oxford Biomedica PLC

23 November 2018

Director Dealings / Market Share Purchase

Oxford, UK - 23 November 2018: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, today announces that Dr. Lorenzo Tallarigo, Chairman of the Group, has purchased 406 ordinary shares of 50p each ("Ordinary Shares") in the Company on 23 November 2018 on the London Stock Exchange at a price of 653.9p per share as set out below under the market share purchase agreement outlined in the Group's announcement on 15 December 2015.

Under the market share purchase agreement, one-third of Dr. Tallarigo's fees as Chairman, after tax, are to be used to purchase ordinary shares in Oxford BioMedica plc on a monthly basis at the prevailing market price.

Following this purchase Dr. Tallarigo holds 47,539 ordinary shares representing 0.07% of the Company.

The below notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail of the number of Ordinary Shares purchased.

 
 1.   Details of the person discharging material responsibilities/person 
       closely associated 
 a.   Name                                         Lorenzo Tallarigo 
 2.   Reason for the notification 
 a.   Position/status                              Chairman 
 b.   Initial notification                         Initial notification 
       /amendment 
3.    Details of the issuer, emission allowance, market 
       participant, auction platform, auctioneer or auction 
       monitor 
 a.   Name                                         Oxford BioMedica plc 
 b.   Legal Entity Identifier                      213800S1GVQNXQ15K851 
4.    Details of the transaction(s); section to be repeated 
       for (i) each type of instrument; (ii) each type of 
       transaction; (iii) each date; and (iv) each place 
       where transactions have been conducted 
 a.   Description of                               Oxford BioMedica plc Ordinary Shares 
       the financial                                of 50p each 
       instrument, type                             GB00BDFBVT43 
       of instrument 
       identification 
       code 
b.    Nature of the                                Purchase of ordinary shares 
       transaction 
c.    Currency                                     GBP - British Pound 
d.    Price(s) and volume(s)                             Price(s)               Volume(s) 
                                 GBP6.539                                          406 
 
e.          Aggregated information                 406 
              *    Aggregated volume                GBP6.539 
                                                    GBP2,654.83 
 
              *    Price 
 
 
              *    Aggregated total 
f.    Date of the transaction                      2018-11-23 
g.    Place of the transaction                     London Stock Exchange, Main Market (XLON) 
 

The issued share capital of the Group is 66,058,261 ordinary 50p shares.

-Ends-

 
 For further information, please contact: 
  Oxford BioMedica plc:                       Tel: [phone] 
   John Dawson, Chief Executive Officer 
   Stuart Paynter, Chief Financial Officer 
  Financial and corporate communications      Tel: [phone] 
   enquiries: 
   Consilium Strategic Communications 
   Mary-Jane Elliott/Matthew Neal/Olivia 
   Manser/Laura Thornton 
 

Notes for editors

About Oxford BioMedica

Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector(R)), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Bioverativ, Sanofi, Axovant, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, GC LabCell and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 360 people. Further information is available at www.oxfordbiomedica.co.uk

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

DSHPGGBWGUPRGUW

(END) Dow Jones Newswires

November 23, 2018 05:41 ET (10:41 GMT)